Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359696 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01359696 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 40 participants.
The verdict
NCT01359696, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.
Interventions
- DRUG gemcitabine
- DRUG GDC-0425
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2011-07-11 |
| Est. Completion | 2014-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359696
The ClinicalTrials.gov registry entry for NCT01359696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT01359696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359696 about?
NCT01359696 is a clinical study titled "A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma". This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.
What is the current status of trial NCT01359696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2011-07-11. Estimated completion is 2014-05-29.
What interventions are being tested in trial NCT01359696?
The interventions under investigation include: gemcitabine (DRUG), GDC-0425 (DRUG).
Who is sponsoring clinical trial NCT01359696?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.